title: Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of beta-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis.
abstract: OBJECTIVE
  The usefulness of 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy in predicting the effectiveness of beta-blocker therapy in dilated cardiomyopathy (DCM) was investigated from the standpoint of long-term prognosis.
  
  
  METHODS
  The subjects were 53 DCM patients in whom beta-blockers had been successfully introduced and used for 6 months or longer. When symptoms were stable before the introduction of beta-blockers and for up to 1 year thereafter, MIBG myocardial single-photon emission computed tomography was performed and the images analysed to obtain the extent score (EXT), severity score (SEV) and washout rate (WR). At the same time, echocardiography was performed to measure left ventricular ejection fraction (LVEF). Thereafter, patients were placed under observation for an average of 1,314+/-986 days, with the occurrence of cardiac events as the endpoint.
  
  
  RESULTS
  The degree of improvement in WR after introduction of beta-blockers was a significant predictor of cardiac events. In fact, none of the patients whose improvement in WR was valued at 10 or higher had cardiac events. Accordingly, using improvement in WR of 10 as the cut-off value, the patients were divided into two groups, "improved" and "unimproved". There were significant differences between the groups in respect of early EXT, early SEV and WR before the introduction of beta-blockers. As regards predictors of WR improvement, multivariate logistic regression analysis demonstrated that early EXT, WR and LVEF were significant predictors.
  
  
  CONCLUSIONS
  This study shows that, from the standpoint of long-term prognosis, DCM patients who would benefit the most from beta-blocker therapy are those with low early EXT and early SEV and high WR before beta-blocker introduction regardless of LVEF values.
authors.affiliation: Division of Cardiovascular Medicine, Department of Internal Medicine, Ohmori Hospital, Toho University School of Medicine, Tokyo, Japan. s-fujimo@tj8.so-net.ne.jp
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Fujimoto
authors.forename: Aritomo
authors.initials: A
authors.lastname: Inoue
authors.forename: Shinji
authors.initials: S
authors.lastname: Hisatake
authors.forename: Shohei
authors.initials: S
authors.lastname: Yamashina
authors.forename: Hisayo
authors.initials: H
authors.lastname: Yamashina
authors.forename: Hajime
authors.initials: H
authors.lastname: Nakano
authors.forename: Junichi
authors.initials: J
authors.lastname: Yamazaki
mesh_terms: D019797:3-Iodobenzylguanidine; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002311:Cardiomyopathy, Dilated / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000319:Adrenergic beta-Antagonists; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine